DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Rhea-AI Summary

DBV Technologies, a clinical-stage biopharmaceutical company, held its 2023 Ordinary and Extraordinary General Meeting on April 12, 2023, chaired by Michel de Rosen. Shareholders approved all resolutions proposed by the Board of Directors. These resolutions reflect the company's ongoing commitment to advancing its innovative Viaskin™ platform, which focuses on epicutaneous immunotherapy for food allergies. DBV Technologies is actively conducting clinical trials for Viaskin Peanut, aimed at improving the treatment landscape for food allergic patients. The company operates globally from Montrouge, France, and Basking Ridge, NJ, with shares traded on Euronext Paris (DBV) and Nasdaq (DBVT).

Positive

• All proposed resolutions by the Board of Directors were approved.
• Ongoing clinical trials of Viaskin Peanut demonstrate progress in food allergy treatment.

Negative

• None.

Montrouge, France, April 12, 2023

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Shareholders Approved All Proposed Resolutions

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies.

The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://www.dbv-technologies.com/events/2023-annual-general-meeting/.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What were the results of DBV Technologies' 2023 General Meeting?

All proposed resolutions by DBV Technologies' Board of Directors were approved during the 2023 General Meeting.

When was the 2023 General Meeting of DBV Technologies held?

The General Meeting was held on April 12, 2023.

What is the focus of DBV Technologies?

DBV Technologies focuses on developing Viaskin™, an epicutaneous immunotherapy platform for treating food allergies.

On which stock exchanges is DBV Technologies listed?

DBV Technologies is listed on Euronext Paris under the ticker DBV and on Nasdaq under the ticker DBVT.